Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

  Female, N (%) Male, N (%) All, N (%)
Number of patients 79 (35.9) 141 (64.1) 220
Age at diagnosis (years)
 Median 77 72 74
 Range 33–93 43–90 33–93
Site of primary tumour
 Distal oesophagus 4 (5.1) 16 (11.3) 20 (9.1)
 GOJ/cardia 17 (21.5) 46 (32.6) 63 (28.6)
 Corpus 21 (26.6) 44 (31.2) 65 (29.5)
 Antrum/pylorus 37 (46.8) 35 (24.8) 72 (32.7)
Tumour differentiation grade
 Grade 1 14 (17.7) 16 (11.3) 30 (13.6)
 Grade 2 33 (41.8) 70 (49.6) 103 (46.8)
 Grade 3 32 (40.5) 55 (39.0) 87 (39.5)
Stage at diagnosis
 IA 15 (19.0) 18 (12.8) 33 (15.0)
 IB 7 (8.9) 19 (13.5) 26 (11.8)
 IIA 17 (21.5) 33 (23.4) 50 (22.7)
 IIB 14 (17.7) 19 (13.5) 33 (15.0)
 IIIA 7 (8.9) 21 (14.9) 28 (12.7)
 IIIB 11 (13.9) 19 (13.5) 30 (13.6)
 IIIC 1 (1.3) 5 (3.5) 6 (2.7)
 IV 7 (8.9) 7 (5.0) 14 (6.4)
Residual tumour classification
 R0 (no residual tumour) 62 (78.5) 105 (74.5) 167 (75.9)
 R1 (microscopic residual tumour) 5 (6.3) 19 (13.5) 24 (10.9)
 R2 (macroscopic residual tumour) 8 (10.1) 9 (6.4) 17 (7.7)
 Rx (unknown) 4 (5.1) 8 (5.7) 12 (5.5)
Perioperative and adjuvant therapya (N = 206)
 Only chemotherapy 7 (9.7) 24 (17.9) 31 (15.0)
 Chemoradiotherapy 4 (5.6) 16 (11.9) 20 (9.7)
 Only radiation therapy 1 (1.4) 4 (3.0) 5 (2.4)
 No adjuvant therapy 58 (80.6) 89 (66.4) 147 (71.4)
 Unknown 2 (2.8) 1 (0.7) 3 (1.5)
Tumour recurrenceb(N = 195)
 No recurrence 55 (79.7) 82 (65.1) 137 (70.3)
 Single metastasis >6 months 10 (14.5) 26 (20.6) 36 (18.5)
 Multiple metastases >6 months 4 (5.8) 18 (14.3) 22 (11.3)
Follow-up status
 Alive and free of disease 22 (27.8) 31 (22.0) 53 (24.1)
 Alive with disease 1 (1.3) 1 (0.7) 2 (0.9)
 Died of disease 43 (54.4) 74 (52.5) 117 (53.2)
 Died of other cause 12 (15.2) 30 (21.3) 42 (19.1)
 Unknown cause of death 1 (1.3) 5 (3.5) 6 (2.7)
  1. GOJ gastro-oesophageal junction
  2. aExcluding stage IV, bExcluding stage IV and recurrence <6 months